Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 13/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31148365 | 0.96 | MAPT (0.47) | MAPTIRAK4POLBPTPN11 | |
| SCHEMBL25418681 | 0.93 | MAPT (0.45) | MAPTPOLBPTPN11 | |
| SCHEMBL30422856 | 0.93 | MAPT (0.45) | MAPTPOLBPTPN11 | |
| Hydrochloric Acid SCHEMBL30422569 | 0.92 | MAPT (0.45) | MAPTPOLBPTPN11 | |
| Trifluoroacetic Acid SCHEMBL31485480 | 0.88 | HTT (0.43) | MAPTPOLBPTPN11 | |
| Trifluoroacetic Acid SCHEMBL31148426 | 0.88 | HTT (0.43) | MAPTPOLBPTPN11 | |
| Trifluoroacetic Acid SCHEMBL30423010 | 0.88 | MAPT (0.38) | MAPTIRAK4POLBPTPN11 | |
| Trifluoroacetic Acid SCHEMBL30422633 | 0.87 | MAPT (0.37) | MAPTPOLBPTPN11 | |
| Trifluoroacetic Acid SCHEMBL31148452 | 0.87 | HTT (0.51) | MAPTPOLBPTPN11 | |
| SCHEMBL25439487 | 0.85 | BCL6 (0.41) | MAPTPOLBPTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| EP-4441042-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Rgenta Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| WO-2023102231-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RTCB, NSUN2, PRPF19 | MAPT 4668/4885IRAK4 2216/4885POLB 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.